Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05050006 · ClinicalTrials.gov registry record · Phase 2
ITIL-168 in Advanced Melanoma
A Phase 2 study, sponsored by Instil Bio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT05050006 is a Phase 2 study that was terminated before completion, run by Instil Bio. The registered enrollment target is 29 participants.
The verdict
NCT05050006, a Phase 2 study, was terminated before completion, sponsored by Instil Bio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
DELTA-1 is a phase 2 clinical trial to evaluate the efficacy and safety of ITIL-168 in adult subjects with advanced melanoma who have previously been treated with a PD-1 inhibitor. ITIL-168 is a cell therapy derived from a patient's own tumor-infiltrating immune cells (lymphocytes; TILs).
Interventions
- BIOLOGICAL ITIL-168
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-10-07 |
| Est. Completion | 2023-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05050006
The ClinicalTrials.gov registry entry for NCT05050006 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Instil Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ITIL-168 is the first listed.
NCT05050006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05050006 about?
NCT05050006 is a clinical study titled "ITIL-168 in Advanced Melanoma". DELTA-1 is a phase 2 clinical trial to evaluate the efficacy and safety of ITIL-168 in adult subjects with advanced melanoma who have previously been treated with a PD-1 inhibitor. ITIL-168 is a cell therapy derived from a patient's own tumor-infiltrating immune cells (lymphocytes; TILs).
What is the current status of trial NCT05050006?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2021-10-07. Estimated completion is 2023-02-27.
What interventions are being tested in trial NCT05050006?
The interventions under investigation include: ITIL-168 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05050006?
This trial is sponsored by Instil Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.